Saturday, October 3, 2026

USD/CNH Falls By 2% In The Last 21 Sessions

ViaNews Editorial Team

November 30, 2023

USD/CNH Falls By 2% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.44% for the last 21 sessions. At 02:13 EST on Thursday, 30 November, USD/CNH (USDCNH) is $7.14.

USD/CNH's yearly highs and lows, it's 0.422% up from its 52-week low and 0.06% down from its 52-week high.

News about

  • Eur/usd remains capped below 1.0950, eyes on eurozone inflation, US GDP data. According to FXStreet on Monday, 27 November, "The downside risks to growth in Germany, Europe's largest economy might exert some selling pressure on the Euro (EUR) and act as a headwind for the EUR/USD pair. "
  • Eur/usd forex signal: euro has more upside ahead - 27 November 2023. According to DailyForex on Monday, 27 November, "The EUR/USD exchange rate has been in a strong bullish trend in the past few days. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bullish viewBuy the EUR/USD pair and set a take-profit at 1.1040."
  • According to FXStreet on Monday, 27 November, "Further north, EUR/USD might face resistance around the August top of 1.1064 (August 10) and another weekly peak of 1.1149 (July 27), all preceding the 2023 high of 1.1275 (July 18)."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com